Insider Transactions of Faeth Therapeutics, Inc.

Anand Kiran Parikh, President and CEO of Faeth Therapeutics, Inc., reported several transactions on June 22, 2026. These include the acquisition of 2,806 shares of Common Stock at $19.76 per share, and the acquisition of 45,252 shares of Common Stock at $1.16 per share. Additionally, 8,213 shares of Common Stock were acquired at $1.16 per share. The filing also details the exercise and disposal of employee stock options. Specifically, 45,252 options with an exercise price of $1.16 were disposed of, with an underlying security of Common Stock. Another 8,213 options with an exercise price of $1.16 were also disposed of, also for Common Stock. Footnote F1 indicates that 12,258 shares vest monthly through January 1, 2027, with the remainder vesting on February 1, 2027. Footnote F2 corrects a clerical error regarding an expiration date to December 1, 2035. Footnote F3 states that shares subject to an option vest in forty-eight successive equal monthly installments starting August 1, 2022.